Skip to main
ANIP

ANI Pharma (ANIP) Stock Forecast & Price Target

ANI Pharma (ANIP) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

ANI Pharmaceuticals is positioned for growth in the biopharmaceutical industry with a diverse portfolio of products in various therapeutic areas. The company's Rare Disease and Brands segment generate the majority of its revenues, while its Generics segment continues to expand with new product offerings. The recent 2Q 2026 earnings were above expectations, driven by strong sales in Generics and Brand Royalties and Other Revenues. Despite moderation in Cortrophin sales for 2Q 2026 and lower FY 2026 guidance, the company expects a meaningful increase in Cortrophin sales in 2H 26 and remains bullish on its longer-term outlook, supported by the expansion of its sales force and new indications for Cortrophin.

Bears say

ANI Pharmaceuticals is experiencing a decline in sales and prescription volumes for their flagship product Cortrophin Gel, leading to a decrease in revenue guidance for 2026. While the company is confident in their ability to meet the new guidance, there are risks associated with clinical, regulatory, and commercial challenges, as well as competition in the generics industry. In addition, the upcoming loss of exclusivity for their Prucalopride product could lead to a decrease in generics revenue for the company in the second quarter of 2026.

ANI Pharma (ANIP) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ANI Pharma (ANIP) Forecast

Analysts have given ANI Pharma (ANIP) a Buy based on their latest research and market trends.

According to 6 analysts, ANI Pharma (ANIP) has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ANI Pharma (ANIP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.